Pharmacokinetic Analysis and Phase 1 Study of MRX-1024 in Patients Treated with Radiation Therapy with or without Cisplatinum for Head and Neck Cancer
Open Access
- 28 April 2010
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 16 (9) , 2666-2676
Abstract
Purpose: A previous study reported radiation protection from mucosal injury with D-methionine (D-met) in preclinical evaluation; therefore, the pharmacokinetics, safety, and utility of D-met were evaluated clinically. Experimental Design: The pharmacokinetics of D-met following oral administration of a bioavailable formulation (MRX-1024) was evaluated in normal volunteers. Subsequently, 25 patients were enrolled on a phase 1 study of MRX-1024 concurrent with radiation therapy (RT) with or without weekly cisplatinum. Toxicity and mucosal events were evaluated weekly. Results: Oral MRX-1024 resulted in rapid and dose-dependent increases in plasma D-met concentrations with a half-life of 3 hours. When administered concurrent with RT without chemotherapy, it was associated with a modest increase in grade 2 (two of six patients) and grade 3 (one of six patients) emesis. In those treated with MRX-1024 along with RT and weekly cisplatinum, there was no appreciable increase in emesis. Overall, five patients withdrew from the study due to emesis (four grade 2 and one grade 3). Only one incidence of dose-limiting toxicity (grade 3 emesis) was identified in 25 patients (4%). Finally, in 18 evaluable patients treated with MRX-1024 at 100 mg/kg twice daily (BID), the incidence of severe (grade 3) oral mucositis was 6% (1 of 18) with no grade 4 mucositis. Conclusions: There is a dose-dependent increase in D-met exposure following MRX-1024 administration at 50 and 100 mg/kg, and MRX-1024 is safe for use concurrent with combined radiation and chemotherapy. The observed rate of mucositis seems less than that for similar treatment regimens within the published literature. Clin Cancer Res; 16(9); 2666–76. ©2010 AACR.Keywords
All Related Versions
This publication has 38 references indexed in Scilit:
- Evaluation of d-Methionine as a Novel Oral Radiation Protector for Prevention of MucositisClinical Cancer Research, 2008
- Antioxidant vitamins supplementation and mortality: A randomized trial in head and neck cancer patientsInternational Journal of Cancer, 2006
- Palifermin for Oral Mucositis after Intensive Therapy for Hematologic CancersNew England Journal of Medicine, 2004
- Oral Sequelae of Head and Neck RadiotherapyCritical Reviews in Oral Biology & Medicine, 2003
- A phase III randomized trial comparing concurrent chemotherapy and radiotherapy with radiotherapy alone in resectable stage III and IV squamous cell head and neck cancer: Preliminary resultsHead & Neck, 1997
- Evaluation of GM-CSF mouthwash for prevention of chemotherapy-induced mucositis: a randomized, double-blind, dose-ranging studyCytokine, 1995
- Prophylaxis of oral mucositis associated with chemoradiotherapy for oral carcinoma by Azelastine hydrochloride (Azelastine) with other antioxidantsHead & Neck, 1994
- Efficacy of oral sucralfate suspension in prevention and treatment of chemotherapy-induced mucositisThe Journal of Pediatrics, 1988
- Methionine in Treatment of Acetaminophen PoisoningNew England Journal of Medicine, 1977
- ORAL METHIONINE IN THE TREATMENT OF SEVERE PARACETAMOL (ACETAMINOPHEN) OVERDOSEThe Lancet, 1976